

Antiviral Activity of Sulphated Specialized Metabolites from Sea Urchin *Clypeaster humilis*: *in vitro* and *in silico* studies

Fahd M. Abdelkarem^a, Hamdy K. Assaf^a, Yaser A. Mostafa^{b,c}, Aldoushy Mahdy^d, Modather F. Hussein^{e,f}, Samir A. Ross^{g,h}, Nesma M. Mohamed^{i,j*}

^aDepartment of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.

^bPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.

^cPharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut, Assiut 77771, Egypt.

^dDepartment of Zoology, Faculty of Science, Al-Azhar University, Assiut, 71524, Egypt.

^eChemistry Department, Collage of Science, Jouf University, P.O. Box 2014, Sakaka 72388, Saudi Arabia.

^fChemistry Department, Faculty of Science, Al-Azhar University, Asyut Branch, Assiut 71524, Egypt.

^gNational Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, USA.

^hDepartment of BioMolecular Sciences, Division of Pharmacognosy, School of Pharmacy, University of Mississippi, University, Mississippi 38677, USA.

ⁱDepartment of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.

^jDepartment of Pharmacognosy, Faculty of Pharmacy, Badr University in Assiut, Assiut 77771, Egypt.

Contents:

NMR data of known compounds.

Figure S1. Negative HR-ESI-MS spectrum of compound **1**.

Figure S2. Expanded negative HR-ESI-MS spectrum of compound **1**.

Figure S3. ^1H -NMR spectrum of compound **1** (400 MHz, CD_3OD).

Figure S4. DEPT-Q spectrum of compound **1** (100 MHz, CD_3OD).

Figure S5. HSQC spectrum of compound **1** (CD_3OD).

Figure S6. HMBC spectrum of compound **1** (CD_3OD).

Figure S7. ^1H - ^1H COSY spectrum of compound **1** (CD_3OD).

Figure S8. Negative HR-ESI-MS spectrum of compound **2**.

Figure S9. ^1H -NMR spectrum of compound **2** (400 MHz, $\text{DMSO-}d_6$).

Figure S10. DEPT-Q spectrum of compound **2** (100 MHz, $\text{DMSO-}d_6$).

Figure S11. HSQC spectrum of compound **2** ($\text{DMSO-}d_6$).

Figure S12. HMBC spectrum of compound **2** ($\text{DMSO-}d_6$).

Figure S13. ^1H - ^1H COSY spectrum of compound **2** ($\text{DMSO-}d_6$).

Figure S14. ^1H -NMR spectrum of compound **3** (400 MHz, $\text{DMSO-}d_6$).

Figure S15. DEPT-Q spectrum of compound **3** (100 MHz, $\text{DMSO-}d_6$).

Figure S16. ^1H -NMR spectrum of compound **4** (400 MHz, $\text{DMSO-}d_6$).

Figure S17. ^{13}C -NMR spectrum of compound **4** (100 MHz, $\text{DMSO-}d_6$).

Figure S18. ^1H -NMR spectrum of compound **5** (500 MHz, $\text{DMSO-}d_6$).

Figure S19. ^{13}C -NMR spectrum of compound **5** (125 MHz, $\text{DMSO-}d_6$).

Figure S20. ^1H -NMR spectrum of compound **6** (500 MHz, $\text{DMSO-}d_6$).

Figure S21. ^{13}C -NMR spectrum of compound **6** (125 MHz, $\text{DMSO-}d_6$).

Figure S22. Negative HR-ESI-MS spectrum of compound **7**.

Figure S23. $^1\text{H-NMR}$ spectrum of compound **7** (500 MHz, CDCl_3).

Figure S24. $^{13}\text{C-NMR}$ spectrum of compound **7** (125 MHz, CDCl_3).

Figure S25. $^1\text{H-NMR}$ spectrum of compound **8** (400 MHz, CDCl_3).

Figure S26. DEPT-Q spectrum of compound **8** (100 MHz, CDCl_3).

Figure S27. Positive HR-ESI-MS spectrum of compound **9**.

Figure S28. $^1\text{H-NMR}$ spectrum of compound **9** (400 MHz, CDCl_3).

Figure S29. DEPT-Q spectrum of compound **9** (100 MHz, CDCl_3).

Figure S30. $^1\text{H-NMR}$ spectrum of compound **10** (400 MHz, CDCl_3).

Figure S31. DEPT-Q spectrum of compound **10** (100 MHz, CDCl_3).

Figure S32. Negative HR-ESI-MS spectrum of compound **11**.

Figure S33. $^1\text{H-NMR}$ spectrum of compound **11** (400 MHz, $\text{DMSO-}d_6$).

Figure S34. DEPT-Q spectrum of compound **11** (100 MHz, $\text{DMSO-}d_6$).

Figure S35. Positive HR-ESI-MS spectrum of compound **12**.

Figure S36. $^1\text{H-NMR}$ spectrum of compound **12** (400 MHz, CD_3OD).

Figure S37. DEPT-Q spectrum of compound **12** (100 MHz, CD_3OD).

Table S1. Chemical quantum descriptors and their equations (1-8).

Table S2. Calculated quantum-chemical parameters of the compounds (**1**, **2** & **11**) using the B3LYP/6-311++G (2d,2p) method.

NMR data of known compounds:

2'-Deoxyuridine (3):

$^1\text{H-NMR}$ spectrum (400 MHz, $\text{DMSO-}d_6$): δ_{H} 7.84 (1H, d, $J = 8.0$, H-4), 6.15 (1H, t, $J = 6.4$, H-1'), 5.61 (1H, d, $J = 8.0$, H-3), 4.22 (1H, m, H-3'), 3.77 (1H, m, H-4'), 3.55 (1H, m, H-5'), 2.07 (2H, m, H-2').

DEPT-Q spectrum (100 MHz, $\text{DMSO-}d_6$): δ_{C} 39.93 (C-2'), 61.26 (C-5'), 70.36 (C-3'), 84.04 (C-1'), 87.04 (C-4'), 101.62 (C-3), 140.56 (C-4), 150.57 (C-2), 163.37 (C-6).

Inosine (4):

$^1\text{H-NMR}$ spectrum (400 MHz, $\text{DMSO-}d_6$): δ_{H} 8.32 (1H, s, H-3), 8.07 (1H, s, H-3), 5.86 (1H, d, $J = 5.6$, H-5), 3.0-5.0 (5H, ribose protons).

$^{13}\text{C-NMR}$ spectrum (100 MHz, $\text{DMSO-}d_6$): δ_{C} 138.6 (C-1), 146.3 (C-2), 148.3 (C-3), 157.2 (C-4), 124.5 (C-5), 87.6 (C-1'), 70.4 (C-2'), 74.1 (C-3'), 85.7 (C-4'), 61.4 (C-5').

Thymidine (5):

$^1\text{H-NMR}$ spectrum (500 MHz, $\text{DMSO-}d_6$): δ_{H} 7.69 (1H, s, H-6), 6.16 (1H, t, $J = 7.0$, H-1'), 4.23 (1H, br.s, H-3'), 3.75 (1H, m, H-4'), 3.59 (1H, dd, $J = 4.0, 12.0$, H-5'a), 3.53 (1H, dd, $J = 4.0, 12.0$, H-5'b), 2.08 (2H, m, H-2'), 1.76 (3H, s, CH_3).

$^{13}\text{C-NMR}$ spectrum (125 MHz, $\text{DMSO-}d_6$): δ_{C} 163.8 (C-4), 150.5 (C-2), 136.2 (C-6), 109.4 (C-5), 87.3 (C-4'), 83.8 (C-1'), 70.5 (C-3'), 61.4 (C-5'), 40.0 (C-2'), 12.3 (CH_3).

Uracil (6):

$^1\text{H-NMR}$ spectrum (500 MHz, $\text{DMSO-}d_6$): δ_{H} 7.38 (1H, d, $J = 8$ Hz) and 5.44 (1H, d, $J = 7.5$ Hz).

$^{13}\text{C-NMR}$ spectrum (125 MHz, $\text{DMSO-}d_6$): δ_{C} 164.4 (C-4), 151.6 (C-2), 142.3 (C-6) and 100.2 (C-5).

Glyceryl monopalmitate (7):

The negative HR-ESI-MS analysis showed a characteristic molecular ion peak $[M+HCOO]^-$ at m/z 375.2772 (calcd for $C_{20}H_{39}O_6$, 375.2747).

1H -NMR spectrum (500 MHz, $CDCl_3$): δ_H 4.21 (1H, dd, $J = 11.5, 4.5$ Hz, H-1a), 4.15 (1H, dd, $J = 12.0, 6.5$ Hz, H-1b), 3.93 (1H, m, H-2), 3.69 (1H, dd, $J = 11.5, 4.0$ Hz, H-3a), 3.61 (1H, dd, $J = 11.5, 6.0$ Hz, H-3b), 2.36 (2H, t, $J = 7.5$ Hz, H-2'), 0.88 (3H, t, $J = 7.0$ Hz, H-16').

^{13}C -NMR spectrum (125 MHz, $CDCl_3$): δ_C 174.5 (C-1), 34.3 (C-2), 32.1 (C-3), 29.8-22.8 (C-4~15), 14.3 (C-16), 65.3 (C-1'), 70.4 (C-2'), 63.5 (C-3').

Benzyl benzoate (8):

1H -NMR spectrum (400 MHz, $CDCl_3$): δ_H 8.10 (2H, d, $J = 8$, H-2'/H-6'), 8.08 (2H, d, $J = 8$, H-2/H-6), 7.58 (1H, t, $J = 7.5$, H-4'), 7.55 (1H, t, $J = 7.5$, H-4), 7.45 (2H, m, H-3'/H-5'), 7.40 (2H, m, H-3/H-5), 5.38 (s, 2H).

DEPT-Q spectrum (100 MHz, $CDCl_3$): δ_C 166.6 (C-7'), 136.3 (C-1), 133.2 (C-4'), 129.8 (C-1'), 128.7 (C-2'/C-6'), 128.5 (C-4), 128.4 (C-3'/C-5'), 128.4 (C-2/C-6), 128.3 (C-3/C-5), 66.8 (C-7).

Methyl-(E)-nonadec-10-enoate (9):

The positive HR-ESI-MS analysis showed a characteristic molecular ion peak $[M+K]^+$ at m/z 349.1776 (calcd for $C_{20}H_{38}KO_2$, 349.2509).

1H -NMR spectrum (400 MHz, $CDCl_3$): δ_H 5.33-5.36 (2H, m, H-11/H-10), 3.66 (3H, s, H-1'), 2.30 (2H, t, $J = 8.0$, H-2), 1.99 (4H, m, H-9/H-12), 1.62 (2H, m, H-3), 1.25-1.32 [22H, m, (H-4 to H-8) and (H-13 to H-18)], 0.88 (3H, t, $J = 7.2$, H-19).

DEPT-Q spectrum (100 MHz, $CDCl_3$): δ_C 174.29 (C-1), 130.14 (C-11), 129.90 (C-10), 51.60 (C-1'), 34.26 (C-2), 31.93 (C-17), 29.88-29.14 [(C-4) to (C-8) and (C-13) to (C-16)], 27.37 (C-12), 27.31 (C-9), 25.10 (C-3), 22.81 (C-18), 14.26 (C-19).

Cholesterol (10):

¹H-NMR spectrum (400 MHz, CDCl₃): δ_H 0.67 (3H, s, H-18), 0.86 (3H, d, J = 6.6, H-26), 0.84 (3H, d, J = 6.6, H-27), 0.91 (3H, d, J = 6.5, H-21), 1.02 (3H, s, H-19), 1.51 (2H, m, H-2), 1.99 (2H, m, H-7), 1.82 (2H, m, H-8), 2.26 (2H, m, H-4), 3.52 (1H, m, H-3), 5.34 (1H, br.d, J = 5.2, H-6).

DEPT-Q spectrum (100 MHz, CDCl₃): δ_C 12.01 (C-18), 18.86 (C-21), 19.55 (C-19), 21.23 (C-11), 22.71 (C-26), 22.98 (C-27), 23.97 (C-23), 24.44 (C-15), 28.16 (C-25), 28.38 (C-16), 31.76 (C-2), 32.02 (C-7), 32.05 (C-8), 35.94 (C-20), 36.33 (C-22), 37.39 (C-10), 39.65 (C-1), 39.66 (C-24), 39.92 (C-12), 42.40 (C-4), 42.41 (C-13), 50.26 (C-9), 56.28 (C-17), 56.90 (C-14), 71.95 (C-3), 121.86 (C-6), 140.86 (C-5).

1,2-Di-O-palmitoyl-3-O-(6'''-sulfo-α-D-quinovopyranosyl)-glycerol (11):

The negative HR-ESI-MS analysis showed a characteristic molecular ion peak [M-H]⁻ at *m/z* 793.5311 (calcd for C₄₁H₇₇O₁₂S, 793.5136).

¹H-NMR spectrum (400 MHz, DMSO-*d*₆): δ_H 5.13 (1H, m, H-2), 4.57 (1H, d, J = 3.6, H-1'''), 4.34 (1H, dd, J = 2.8, 12.0, H-1a), 4.14 (1H, dd, J = 7.6, 12.0, H-1b), 3.88 (1H, dd, J = 6.0, 10.4, H-3a), 3.39 (1H, m, H-3b), 3.77 (1H, m, H-5'''), 3.34 (1H, m, H-3'''), 3.18 (1H, m, H-2'''), 2.92 (1H, m, H-4'''), 2.90 (1H, dd, J = 4.4, 14.0, H-6'''a), 2.55 (1H, dd, J = 6.8, 14.0, H-6'''a), 2.27 (2H, m, H-2'), 2.27 (2H, m, H-2''), 1.49 (2H, m, H-3'), 1.49 (2H, m, H-3''), 1.23 (24H, m, H-4' to H-15'), 1.23 (24H, m, H-4'' to H-15''), 0.85 (3H, t, J = 7.2, H-16'), 0.85 (3H, t, J = 7.2, H-16'').

DEPT-Q spectrum (100 MHz, DMSO-*d*₆): δ_C 172.55 (C-1'), 172.39 (C-1''), 98.29 (C-1'''), 74.29 (C-4'''), 72.91 (C-3'''), 71.63 (C-2'''), 69.73 (C-2), 68.56 (C-5'''), 64.61 (C-3), 62.65 (C-1), 54.57 (C-6'''), 33.58 (C-2'), 33.45 (C-2''), 31.33 (C-3'), 31.33 (C-3''), 29.11-22.13 (C-4') to (C-15'), 29.11-22.13 (C-4'') to (C-15''), 13.97 (C-16'), 13.97 (C-16'').

Boldine (12):

The positive HR-ESI-MS analysis (Figure S35) showed a characteristic molecular ion peak $[M+H]^+$ at m/z 328.1589 (calcd for $C_{19}H_{22}NO_4$, 328.1549).

1H -NMR spectrum (400 MHz, CD_3OD): δ_H 2.76 (3H, s, N-CH₃), 2.60-2.78 (3H, m, H-7b, H-4), 2.88-3.12 (4H, m, H-6a, H-5, H-7a), 3.58 (3H, s, 2-OCH₃), 3.86 (3H, s, 10-OCH₃), 6.59 (1H, s, H-3), 6.76 (1 H, s, H-8), 7.96 (1H, s, H-11).

DEPT-Q spectrum (100 MHz, CD_3OD): δ_C 28.05 (C-4), 33.74 (C-7), 42.64 (N-CH₃), 53.92 (C-5), 56.57 (10- OCH₃), 60.34 (1-OCH₃), 63.77 (C-6a), 112.73 (C-11), 115.14 (C-3), 115.98 (C-8), 124.02 (C-11c), 124.38 (C-11b), 128.17 (C-11a), 128.96 (C-3a), 129.36 (C-7a), 144.77 (C-1), 147.39 (C-9), 148.06 (C-10), 151.41 (C-2).




Figure S1. Negative HR-ESI-MS spectrum of compound **1**.




Figure S2. Expanded negative HR-ESI-MS spectrum of compound **1**.




Figure S3. ¹H-NMR spectrum of compound **1** (400 MHz, CD₃OD).




Figure S4. DEPT-Q spectrum of compound 1 (100 MHz, CD₃OD).




Figure S5. HSQC spectrum of compound **1** (CD₃OD).




Figure S6. HMBC spectrum of compound **1** (CD_3OD).




Figure S7. ^1H - ^1H COSY spectrum of compound **1** (CD_3OD).




Figure S8. Negative HR-ESI-MS spectrum of compound **2**.




Figure S9. $^1\text{H-NMR}$ spectrum of compound **2** (400 MHz, $\text{DMSO-}d_6$).




Figure S10. DEPT-Q spectrum of compound **2** (100 MHz, DMSO-*d*₆).




Figure S11. HSQC spectrum of compound **2** (DMSO-*d*₆).




Figure S12. HMBC spectrum of compound **2** (DMSO-*d*₆).




Figure S13. ¹H-¹H COSY spectrum of compound **2** (DMSO-*d*₆).




Figure S14. $^1\text{H-NMR}$ spectrum of compound **3** (400 MHz, $\text{DMSO-}d_6$).




Figure S15. DEPT-Q spectrum of compound 3 (100 MHz, DMSO- d_6).




Figure S16. $^1\text{H-NMR}$ spectrum of compound **4** (400 MHz, $\text{DMSO-}d_6$).




Figure S17. ^{13}C -NMR spectrum of compound 4 (100 MHz, $\text{DMSO-}d_6$).




Figure S18. ¹H-NMR spectrum of compound **5** (500 MHz, DMSO-*d*₆).




Figure S19. ^{13}C -NMR spectrum of compound **5** (125 MHz, $\text{DMSO-}d_6$).




Figure S20. ^1H -NMR spectrum of compound **6** (500 MHz, $\text{DMSO-}d_6$).




Figure S21. ^{13}C -NMR spectrum of compound 6 (125 MHz, $\text{DMSO-}d_6$).




Figure S22. Negative HR-ESI-MS spectrum of compound 7.




Figure S23. ¹H-NMR spectrum of compound 7 (500 MHz, CDCl₃).




Figure S24. ^{13}C -NMR spectrum of compound 7 (125 MHz, CDCl_3).




Figure S25. ¹H-NMR spectrum of compound **8** (400 MHz, CDCl₃).




Figure S26. DEPT-Q spectrum of compound 8 (100 MHz, CDCl_3).




Figure S27. Positive HR-ESI-MS spectrum of compound **9**.




Figure S28. $^1\text{H-NMR}$ spectrum of compound **9** (400 MHz, CDCl_3).




Figure S29. DEPT-Q spectrum of compound 9 (100 MHz, CDCl_3).




Figure S30. ¹H-NMR spectrum of compound **10** (400 MHz, CDCl₃).




Figure S31. DEPT-Q spectrum of compound **10** (100 MHz, CDCl_3).




Figure S32. Negative HR-ESI-MS spectrum of compound **11**.




Figure S33. $^1\text{H-NMR}$ spectrum of compound **11** (400 MHz, $\text{DMSO-}d_6$).




Figure S34. DEPT-Q spectrum of compound **11** (100 MHz, DMSO- d_6).




Figure S35. Positive HR-ESI-MS spectrum of compound **12**.




Figure S36. $^1\text{H-NMR}$ spectrum of compound **12** (400 MHz, CD_3OD).




Figure S37. DEPT-Q spectrum of compound **12** (100 MHz, CD₃OD).

Table S1. Chemical quantum descriptors and their equations (1-8).

DFT parameter	Equations
Energy gap (ΔE)	$\Delta E = E_{LUMO} - E_{HOMO}$
Ionization potential (I)	$I = -E_{HOMO}$
Hardness (η)	$\eta = (I - A) / 2$
Softness (σ)	$\sigma = 1/2\eta$
Chemical potential (μ)	$\mu = -\chi \cong (E_{HOMO} + E_{LUMO}) / 2$
Electronegativity (χ)	$\chi = (I + A)/2$
Electron Affinity (A)	$A = -E_{LUMO}$
Electrophilicity (ω)	$\omega = \mu^2/2\eta$

Table S2. Calculated quantum-chemical parameters of the compounds (**1**, **2** and **11**) using the B3LYP/6-311++G (2d,2p) method.

Compunds	ELUMO	EHOMO	ΔE	A	I	X	η	s	ω	ΔN max	ΔN
1	-0.13963	-0.2043	0.06467	0.13963	0.2043	0.171965	0.032335	30.92624	0.91455	2.659116	105.5827
2	-0.15414	-0.3063	0.15216	0.15414	0.3063	0.23022	0.07608	13.14406	0.696652	1.513013	44.49119
12	-0.12027	-0.275	0.15473	0.12027	0.275	0.197635	0.077365	12.92574	0.504874	1.277289	43.96281